About Novartis Oncology

When science and passion connect, innovation happens. The oncology community shares a common mission: to transform the way patients live with cancer and related diseases. At Novartis Oncology, we are passionate about the discovery and development of innovative medicines. We seek to provide a broad range of new therapies as well as practical solutions to advance the care of patients.

With nearly 7,000 employees operating in 55 countries, Novartis Oncology has a truly global reach. We have the advantage of extraordinarily talented and globally diverse employees who, through shared goals and different perspectives, are dedicated to transforming the lives of patients living with cancer around the world. We have developed five new practice-changing medicines in the past decade, addressing unmet medical needs in patients worldwide. Our broad pipeline includes 27 new molecular entities in development, targeting key molecular pathways in cancer biology.

Visit Novartis.com to learn more about our group of companies.

Connecting within the oncology community

Making connections in science and building relationships with people in the oncology community fuels our ability to deliver innovative medicines for patients. More than a decade ago, Novartis AG was the first company to form a dedicated global business unit for developing and launching innovative oncology medicines that address the unmet medical needs of patients. This early vision has led to one of the most dynamic portfolios of new products in the marketplace.

Turning scientific possibility into clinical reality

A decade of success in oncology drug development has taught us the value of our connections within the oncology community and their importance to innovation. Together, we explore novel compounds in clinical development, many with potential best-in-class status, aiming to advance or create new standards of care. Our strategy is composed of three elements:

• Targeted research accelerates development and improves results.
• Collaboration leads to breakthroughs.
• Patient-inspired solutions provide more than medicine.

Unique, dedicated global capabilities support our strategy.

Together, we make innovation happen.

Learn more at Novartisoncology.com.

Find out more about our other breakthrough products by choosing a link below.

AFINITOR^®

AFINITOR is indicated for the treatment of hormone receptor-positive (HR+), HER2/neu-negative (HER2-) advanced breast cancer (HR+ advanced breast cancer), in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.¹

AFINITOR is indicated for the treatment of unresectable or metastatic, well-or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.

AFINITOR is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy.

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

For more information and product details, please visit the Global AFINITOR brand website: Afinitor.com.

(For Non US Health Care Professionals Only)

EXJADE^®

EXJADE is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged 6 years and older.

EXJADE is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:

• in patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥7 ml/kg/month of packed red blood cells) aged 2 to 5 years.
• in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (<7 ml/kg/month of packed red blood cells) aged 2 years and older.
• in patients with other anaemias aged 2 years and older.

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

For more information and product details, please visit the Global EXJADE brand website: Exjade.com.

(For Non US Health Care Professionals Only)

FEMARA^®

FEMARA (letrozole) 2.5 mg tablets are approved for the adjuvant (following surgery) treatment of postmenopausal women with hormone receptor-positive early stage breast cancer.

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

For more information and product details, please visit the FEMARA brand website: Femara.com.

(For US Health Care Professionals Only)

GLIVEC^®

GLIVEC (imatinib), which is known as "Gleevec" in the United States, is a cancer treatment indicated for:

• Adult and pediatric patients with newly diagnosed Philadelphia chromosome (bcr–abl) positive (Ph+) Chronic Myeloid Leukemia for whom bone marrow transplantation is not considered as the first line of treatment.
• Adult and pediatric patients with Ph+ Chronic Myeloid Leukemia in chronic phase after failure of interferon-alfa therapy, or in accelerated phase or blast crisis.
• Adult patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) integrated with chemotherapy.
• Adult patients with relapsed or refractory Ph+ ALL as monotherapy.
• Adult patients with myelodysplastic syndrome/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene rearrangements.
• Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) with FIP1L1-PDGFRa rearrangement.

GLIVEC is also indicated for:

• Adult patients with Kit (CD117)-positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).
• Adjuvant treatment of adult patients who are at significant risk of relapse following resection of KIT(CD 117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.
• Adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

For more information and product details, please visit the Global GLIVEC brand website: Glivec.com.

(For Non US Health Care Professionals Only)

JAKAVI^®

JAKAVI (INC424, ruxolitinib) is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

Novartis licensed INC424 (ruxolitinib) from Incyte for development and commercialization outside the US. Incyte has retained rights for the development and commercialization of INC424 (ruxolitinib) in the US.

For more information and product details, please visit the Global JAKAVI brand website: Jakavi.com.

(For Non U.S. Health Care Professionals Only)

SANDOSTATIN^® LAR^®

SANDOSTATIN LAR Depot (octreotide acetate for injectable suspension) is a prescription medicine indicated for patients in whom initial treatment with immediate release SANDOSTATIN^® (octreotide acetate) Injection has been shown to be effective and tolerated for:

• Long-term maintenance therapy in acromegalic patients who have had inadequate response to surgery and/or radiotherapy or for whom surgery and/or radiotherapy is not an option (the goal of treatment in acromegaly is to reduce GH and IGF-1 levels to normal)
• Long-term treatment of the severe diarrhea and flushing episodes associated with metastatic carcinoid tumors
• Long-term treatment of the profuse watery diarrhea associated with VIP-secreting tumors
• In patients with carcinoid syndrome and VIPomas, the effect of SANDOSTATIN Injection and SANDOSTATIN LAR Depot on tumor size, rate of growth and development of metastases has not been determined.

This information is based on the SANDOSTATIN LAR Core Data Sheet. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

For more information and product details, visit the Global SANDOSTATIN LAR brand website: Sandostatin.com.

(For Non US Health Care Professionals Only)

SIGNIFOR^®

SIGNIFOR (pasireotide) is indicated for adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed.

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

For more information and product details, visit the Global SIGNIFOR brand website: Signifor.com.

(For Non US Health Care Professionals Only)

TASIGNA^®

TASIGNA (nilotinib) is a cancer treatment for adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in the chronic phase. Tasigna is also approved for the treatment of chronic phase and accelerated phase Ph+ CML in adult patients resistant or intolerant to at least one prior therapy, including imatinib.

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

For more information and product details, visit the Global TASIGNA brand website: Tasigna.com.

(For Non US Health Care Professionals Only)

VOTUBIA^®

Votubia (everolimus) tablets* is approved for the treatment of patients aged 3 years and older with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery. The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease-related symptoms, has not been demonstrated.

Votubia targets mTOR, a protein that acts as an important regulator of tumor cell division, blood vessel growth and cell metabolism.

For more information on other areas of research, please visit EVEROLIMUS in the research section.

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative. Everolimus is not approved for this indication in all countries.

*Known as Votubia (everolimus) tablets for this patient population in the EU and Switzerland. Approved in the US for this patient population under the trade name Afinitor (everolimus) tablets.

For more information and product details, visit the Global VOTUBIA brand website: Votubia.com.